Thorac cardiovasc Surg 2017; 65(07): 542-545
DOI: 10.1055/s-0036-1583167
Original Thoracic
Georg Thieme Verlag KG Stuttgart · New York

Management and Surgical Outcomes of Concurrent Tuberculosis and Lung Cancer

Serdar Evman1, Volkan Baysungur1, Levent Alpay1, Bahadir Uskul1, Aysun Kosif Misirlioglu1, Serda Kanbur1, Talha Dogruyol1
  • 1Department of Thoracic Surgery, Süreyyapaşa Training and Research Hospital, Istanbul, Turkey
Further Information

Publication History

11 January 2016

13 March 2016

Publication Date:
25 April 2016 (eFirst)


Background Concurrent pulmonary tuberculosis (TB) and lung cancer are rarely encountered in Western countries; however, it is more common in developing countries. We aim to share the diagnostic and treatment approaches in this study.

Materials and Methods Clinical files of all patients undergoing lung resection for non–small cell carcinoma with concurrent pulmonary TB between February 2006 and December 2012 were investigated retrospectively in terms of patient characteristics, operation methods, definite pathology and stage of tumor, postoperative treatment schemes, and associated complications.

Results TB was detected in 17 (1.3%) of 1,266 operated carcinoma patients. Eleven had squamous cell carcinoma and six had adenocarcinoma. Mean age was 54.9 years. Two patients received anti-TB treatment preoperatively. Fifteen patients were given anti-TB treatment postoperatively, as soon as definite microbiological confirmation was obtained, and concurrently given adjuvant therapy after 3 weeks of sole four-drug TB treatment. Pneumonectomy was performed in four (23.5%), sleeve lobectomy in three (17.6%), lobectomy in eight (47%), and bilobectomy in two (11.7%) patients. Postoperative complications occurred in four (23.5%) patients, with bronchopleural fistula being seen in only one pneumonectomy patient. No postoperative mortality or reactivation of TB was seen. Mean survival time was 32 ± 2 months.

Conclusion Resection following a 3-week anti-TB treatment or concurrent anti-TB and postoperative adjuvant chemotherapy does not constitute an additional postoperative risk for patients with concomitant lung malignancy and pulmonary TB. The determination of optimum treatment for these patients presents a challenge in developing countries, where TB is still a common disease.